Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results